Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Mauna Kea Technologies

BATS-CHIXE:MKEAP
Snowflake Description

High growth potential and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MKEAP
BATS-CHIXE
€29M
Market Cap
  1. Home
  2. GB
  3. Healthcare
Company description

Mauna Kea Technologies SA, a medical device company, designs, develops, and markets endomicroscopy and optical biopsy tools for the diagnosis and treatment of gastrointestinal cancers and other diseases worldwide. The last earnings update was 195 days ago. More info.


Add to Portfolio Compare Print
  • Mauna Kea Technologies has significant price volatility in the past 3 months.
MKEAP Share Price and Events
7 Day Returns
6.4%
BATS-CHIXE:MKEAP
-1.2%
GB Medical Equipment
0.1%
GB Market
1 Year Returns
-33.3%
BATS-CHIXE:MKEAP
-0.3%
GB Medical Equipment
-23.6%
GB Market
MKEAP Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Mauna Kea Technologies (MKEAP) 6.4% -18% -44.2% -33.3% -67.4% -81.7%
GB Medical Equipment -1.2% -12% -19.1% -0.3% -2.3% 20.9%
GB Market 0.1% -15.5% -27% -23.6% -24.3% -23.5%
1 Year Return vs Industry and Market
  • MKEAP underperformed the Medical Equipment industry which returned -0.3% over the past year.
  • MKEAP underperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned -23.6% over the past year.
Price Volatility
MKEAP
Industry
5yr Volatility vs Market

Value

 Is Mauna Kea Technologies undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Mauna Kea Technologies to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Mauna Kea Technologies.

BATS-CHIXE:MKEAP Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.3%
Perpetual Growth Rate 10-Year GB Government Bond Rate 0.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BATS-CHIXE:MKEAP
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year GB Govt Bond Rate 0.5%
Equity Risk Premium S&P Global 6.1%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.81
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.808 (1 + (1- 33%) (21.69%))
0.95
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.95
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.53% + (0.95 * 6.07%)
6.3%

Discounted Cash Flow Calculation for BATS-CHIXE:MKEAP using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Mauna Kea Technologies is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

BATS-CHIXE:MKEAP DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 6.3%)
2020 -10.15 Analyst x2 -9.55
2021 -7.20 Analyst x2 -6.37
2022 -0.20 Analyst x1 -0.17
2023 3.90 Analyst x1 3.06
2024 7.30 Analyst x1 5.38
2025 10.16 Est @ 39.18% 7.04
2026 12.96 Est @ 27.58% 8.45
2027 15.49 Est @ 19.47% 9.50
2028 17.62 Est @ 13.79% 10.17
2029 19.35 Est @ 9.81% 10.51
Present value of next 10 years cash flows €38.00
BATS-CHIXE:MKEAP DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= €19.35 × (1 + 0.53%) ÷ (6.3% – 0.53%)
€337.39
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €337.39 ÷ (1 + 6.3%)10
€183.23
BATS-CHIXE:MKEAP Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €38.00 + €183.23
€221.23
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €221.23 / 30.51
€7.25
BATS-CHIXE:MKEAP Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in BATS-CHIXE:MKEAP represents 1.02181x of ENXTPA:MKEA
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
1.02181x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 7.25 x 1.02181
€7.41
Value per share (EUR) From above. €7.41
Current discount Discount to share price of €0.98
= -1 x (€0.98 - €7.41) / €7.41
86.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Mauna Kea Technologies is available for.
Intrinsic value
>50%
Share price is €0.98 vs Future cash flow value of €7.41
Current Discount Checks
For Mauna Kea Technologies to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Mauna Kea Technologies's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Mauna Kea Technologies's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Mauna Kea Technologies's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Mauna Kea Technologies's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BATS-CHIXE:MKEAP PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in EUR €-0.56
ENXTPA:MKEA Share Price ** ENXTPA (2020-04-07) in EUR €0.96
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PE Ratio Median Figure of 11 Publicly-Listed Medical Equipment Companies 25.55x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 748 Publicly-Listed Companies 12.61x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Mauna Kea Technologies.

BATS-CHIXE:MKEAP PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:MKEA Share Price ÷ EPS (both in EUR)

= 0.96 ÷ -0.56

-1.73x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Mauna Kea Technologies is loss making, we can't compare its value to the GB Medical Equipment industry average.
  • Mauna Kea Technologies is loss making, we can't compare the value of its earnings to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does Mauna Kea Technologies's expected growth come at a high price?
Raw Data
BATS-CHIXE:MKEAP PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.73x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
50.6%per year
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PEG Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 2x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 517 Publicly-Listed Companies 0.99x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Mauna Kea Technologies, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Mauna Kea Technologies's assets?
Raw Data
BATS-CHIXE:MKEAP PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in EUR €0.01
ENXTPA:MKEA Share Price * ENXTPA (2020-04-07) in EUR €0.96
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PB Ratio Median Figure of 20 Publicly-Listed Medical Equipment Companies 2.83x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,323 Publicly-Listed Companies 1.11x
BATS-CHIXE:MKEAP PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:MKEA Share Price ÷ Book Value per Share (both in EUR)

= 0.96 ÷ 0.01

73.19x

* Primary Listing of Mauna Kea Technologies.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Mauna Kea Technologies is overvalued based on assets compared to the GB Medical Equipment industry average.
X
Value checks
We assess Mauna Kea Technologies's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Mauna Kea Technologies has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Mauna Kea Technologies expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
50.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Mauna Kea Technologies expected to grow at an attractive rate?
  • Mauna Kea Technologies's earnings growth is expected to exceed the low risk savings rate of 0.5%.
Growth vs Market Checks
  • Mauna Kea Technologies's earnings growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
  • Mauna Kea Technologies's revenue growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
Annual Growth Rates Comparison
Raw Data
BATS-CHIXE:MKEAP Future Growth Rates Data Sources
Data Point Source Value (per year)
BATS-CHIXE:MKEAP Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 50.6%
BATS-CHIXE:MKEAP Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 29.3%
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 21.1%
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 6.2%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 15.5%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 2.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BATS-CHIXE:MKEAP Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BATS-CHIXE:MKEAP Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 39 9 7 1
2023-12-31 31 4 2 1
2022-12-31 25 2 1 1
2021-12-31 15 -2 -7 2
2020-12-31 9 -7 -10 1
2020-04-07
2019-12-31 8 -10 -12 2
BATS-CHIXE:MKEAP Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-06-30 9 -9 -14
2019-03-31 9 -10 -13
2018-12-31 8 -11 -13
2018-09-30 8 -11 -12
2018-06-30 7 -10 -11
2018-03-31 8 -10 -11
2017-12-31 8 -10 -10
2017-09-30 8 -9 -10
2017-06-30 8 -9 -11
2017-03-31 9 -8 -10
2016-12-31 10 -8 -10
2016-09-30 10 -8 -10

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Mauna Kea Technologies's earnings are expected to grow significantly at over 20% yearly.
  • Mauna Kea Technologies's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BATS-CHIXE:MKEAP Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Mauna Kea Technologies Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:MKEAP Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31 -0.34 -0.34 -0.34 1.00
2020-12-31 -0.40 -0.40 -0.40 1.00
2020-04-07
2019-12-31 -0.44 -0.44 -0.44 1.00
BATS-CHIXE:MKEAP Past Financials Data
Date (Data in EUR Millions) EPS *
2019-06-30 -0.56
2019-03-31 -0.53
2018-12-31 -0.51
2018-09-30 -0.50
2018-06-30 -0.48
2018-03-31 -0.48
2017-12-31 -0.49
2017-09-30 -0.51
2017-06-30 -0.54
2017-03-31 -0.55
2016-12-31 -0.55
2016-09-30 -0.59

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Mauna Kea Technologies will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Mauna Kea Technologies's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Mauna Kea Technologies has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Mauna Kea Technologies performed over the past 5 years?

  • Mauna Kea Technologies's last earnings update was 195 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Mauna Kea Technologies's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Mauna Kea Technologies does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Mauna Kea Technologies's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Mauna Kea Technologies's 1-year growth to the GB Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Mauna Kea Technologies's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Mauna Kea Technologies Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:MKEAP Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 9.18 -14.05 14.06 4.57
2019-03-31 8.54 -13.42 13.50 4.66
2018-12-31 7.90 -12.79 12.94 4.76
2018-09-30 7.61 -12.04 12.11 4.62
2018-06-30 7.31 -11.29 11.27 4.48
2018-03-31 7.57 -10.77 11.06 4.46
2017-12-31 7.83 -10.25 10.86 4.44
2017-09-30 8.16 -10.43 11.52 4.42
2017-06-30 8.48 -10.61 12.19 4.41
2017-03-31 9.08 -10.18 12.30 4.40
2016-12-31 9.67 -9.74 12.41 4.40
2016-09-30 9.93 -9.91 12.93 4.37
2016-06-30 10.18 -10.07 13.44 4.33
2016-03-31 10.08 -11.36 14.56 4.49
2015-12-31 9.98 -12.64 15.68 4.65
2015-09-30 10.94 -13.39 16.56 4.83
2015-06-30 11.91 -14.13 17.44 5.00
2015-03-31 12.08 -14.05 17.58 4.79
2014-12-31 12.26 -13.97 17.72 4.58
2014-09-30 11.83 -13.10 17.07 4.21
2014-06-30 11.40 -12.24 16.42 3.84
2014-03-31 11.12 -11.88 16.06 3.72
2013-12-31 10.84 -11.52 15.70 3.61
2013-09-30 10.68 -12.12 16.21 3.72
2013-06-30 10.52 -12.73 16.71 3.82

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Mauna Kea Technologies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Mauna Kea Technologies has efficiently used its assets last year compared to the GB Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Mauna Kea Technologies improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Mauna Kea Technologies's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Mauna Kea Technologies has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Mauna Kea Technologies's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Mauna Kea Technologies's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Mauna Kea Technologies's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Mauna Kea Technologies's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Mauna Kea Technologies's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Mauna Kea Technologies Company Filings, last reported 9 months ago.

BATS-CHIXE:MKEAP Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 0.33 5.37 0.06
2019-03-31 0.33 5.37 0.06
2018-12-31 7.98 7.06 8.69
2018-09-30 7.98 7.06 8.69
2018-06-30 13.74 7.08 15.17
2018-03-31 13.74 7.08 15.17
2017-12-31 16.74 6.95 17.58
2017-09-30 16.74 6.95 17.58
2017-06-30 8.17 6.82 9.66
2017-03-31 8.17 6.82 9.66
2016-12-31 11.16 3.04 9.15
2016-09-30 11.16 3.04 9.15
2016-06-30 9.00 2.61 5.80
2016-03-31 9.00 2.61 5.80
2015-12-31 14.09 2.90 10.69
2015-09-30 14.09 2.90 10.69
2015-06-30 16.86 3.03 12.33
2015-03-31 16.86 3.03 12.33
2014-12-31 18.17 3.24 15.15
2014-09-30 18.17 3.24 15.15
2014-06-30 24.03 3.39 20.11
2014-03-31 24.03 3.39 20.11
2013-12-31 30.16 3.30 28.00
2013-09-30 30.16 3.30 28.00
2013-06-30 34.34 3.73 31.64
  • Mauna Kea Technologies's level of debt (1621.5%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (14.1% vs 1621.5% today).
  • Operating cash flow is negative therefore debt is not well covered.
  • Unable to confirm if the interest payments on Mauna Kea Technologies's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess Mauna Kea Technologies's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Mauna Kea Technologies has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Mauna Kea Technologies's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Mauna Kea Technologies dividends. Estimated to be 0% next year.
If you bought €2,000 of Mauna Kea Technologies shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Mauna Kea Technologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Mauna Kea Technologies's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BATS-CHIXE:MKEAP Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 2.2%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 588 Stocks 5.6%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1.3%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 2.6%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 7.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BATS-CHIXE:MKEAP Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2020-04-07
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Mauna Kea Technologies has not reported any payouts.
  • Unable to verify if Mauna Kea Technologies's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Mauna Kea Technologies's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Mauna Kea Technologies has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Mauna Kea Technologies's dividends in 3 years as they are not expected to pay a notable one for United Kingdom of Great Britain and Northern Ireland.
X
Income/ dividend checks
We assess Mauna Kea Technologies's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Mauna Kea Technologies afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Mauna Kea Technologies has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Mauna Kea Technologies's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Rob Gershon
COMPENSATION €825,498
AGE 52
TENURE AS CEO 1.5 years
CEO Bio

Mr. Robert L. Gershon, also known as Rob, has been Chief Executive Officer and Director at Mauna Kea Technologies SA since October 22, 2018. He served as the Chief Executive Officer of Bovie Medical Corporation since December 13, 2013 until December 15, 2017. Mr. Gershon has over 25 years of healthcare industry experience. On the operations side he ran the largest sales and marketing business at Covidien. He also served as Vice President of Sales and Marketing at Henry Schein ($1.4 billion shared P&L for medical division/$115 million full P&L for dialysis division) and earlier in his career spent over 13 years as a healthcare consultant for Booz, Allen, KPMG and two boutique consultancies where his practice focused on strategic planning, business development and mergers and acquisitions. He served as Director of Bovie Medical Corp. since December 2013 until December 15, 2017. Mr. Gershon received an MBA from J.L. Kellogg Graduate School of Management at Northwestern University and a BSBA degree from American University.

CEO Compensation
  • Insufficient data for Rob to compare compensation growth.
  • Rob's remuneration is higher than average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team Tenure

Average tenure and age of the Mauna Kea Technologies management team in years:

2
Average Tenure
52
Average Age
  • The tenure for the Mauna Kea Technologies management team is about average.
Management Team

Sacha Loiseau

TITLE
Co-Founder & Chairman
COMPENSATION
€639K
TENURE
20.3 yrs

Rob Gershon

TITLE
CEO & Director
COMPENSATION
€825K
AGE
52
TENURE
1.5 yrs

Christophe Lamboeuf

TITLE
CFO & Deputy CEO
TENURE
2 yrs

John Soto

TITLE
Chief Operating Officer
AGE
55
TENURE
3.2 yrs

François Lacombe

TITLE
Chief Scientific Officer

Bruno Villaret

TITLE
Global Director of Sales

Jack McCarthy

TITLE
Chief Marketing Officer
AGE
52
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the Mauna Kea Technologies board of directors in years:

2.7
Average Tenure
52
Average Age
  • The average tenure for the Mauna Kea Technologies board of directors is less than 3 years, this suggests a new board.
Board of Directors

Sacha Loiseau

TITLE
Co-Founder & Chairman
COMPENSATION
€639K
TENURE
1.5 yrs

Rob Gershon

TITLE
CEO & Director
COMPENSATION
€825K
AGE
52
TENURE
1.5 yrs

Chris McFadden

TITLE
Independent Director
TENURE
12.3 yrs

Molly O'Neill

TITLE
Independent Director
COMPENSATION
€34K
AGE
55
TENURE
2.3 yrs

Joe Devivo

TITLE
Independent & Non-Executive Director
COMPENSATION
€43K
AGE
52
TENURE
3.9 yrs

Jennifer Tseng

TITLE
Independent Director
TENURE
3.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Mauna Kea Technologies's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Mauna Kea Technologies has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Mauna Kea Technologies SA, a medical device company, designs, develops, and markets endomicroscopy and optical biopsy tools for the diagnosis and treatment of gastrointestinal cancers and other diseases worldwide. Its flagship product is Cellvizio, a confocal miniprobe endomicroscopy system, which provides physicians and researchers with high-resolution images of tissues at the cellular level. The company was founded in 2000 and is headquartered in Paris, France.

Details
Name: Mauna Kea Technologies SA
MKEAP
Exchange: BATS-CHIXE
Founded: 2000
€29,382,996
30,511,938
Website: http://www.maunakeatech.com
Address: Mauna Kea Technologies SA
9, rue d'Enghien,
Paris,
Ile-de-France, 75010,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA MKEA Ordinary Shares Euronext Paris FR EUR 05. Jul 2011
OTCPK MKEA.F Ordinary Shares Pink Sheets LLC US USD 05. Jul 2011
DB 1MK Ordinary Shares Deutsche Boerse AG DE EUR 05. Jul 2011
LSE 0P5I Ordinary Shares London Stock Exchange GB EUR 05. Jul 2011
BATS-CHIXE MKEAP Ordinary Shares BATS 'Chi-X Europe' GB EUR 05. Jul 2011
Number of employees
Current staff
Staff numbers
99
Mauna Kea Technologies employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/07 23:09
End of day share price update: 2020/04/07 00:00
Last estimates confirmation: 2020/02/03
Last earnings filing: 2019/09/25
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.